LivaNova (NASDAQ:LIVN) Cut to Buy at StockNews.com

StockNews.com cut shares of LivaNova (NASDAQ:LIVN) from a strong-buy rating to a buy rating in a report issued on Wednesday morning.

A number of other research analysts also recently issued reports on LIVN. Mizuho dropped their price target on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. Baird R W upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. The Goldman Sachs Group began coverage on LivaNova in a report on Friday, October 4th. They set a “buy” rating and a $65.00 price target for the company. Needham & Company LLC reissued a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a research report on Monday, November 25th. Finally, Robert W. Baird upped their target price on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $69.17.

LivaNova Price Performance

LivaNova stock opened at $46.56 on Wednesday. The stock’s 50 day moving average is $50.93 and its 200 day moving average is $50.82. LivaNova has a one year low of $43.15 and a one year high of $64.47. The firm has a market cap of $2.53 billion, a P/E ratio of 110.86 and a beta of 0.98. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

Insider Transactions at LivaNova

In other news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the sale, the director now owns 7,522 shares in the company, valued at $383,546.78. The trade was a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.27% of the company’s stock.

Institutional Trading of LivaNova

Several hedge funds have recently bought and sold shares of LIVN. Arizona State Retirement System raised its holdings in LivaNova by 2.0% during the second quarter. Arizona State Retirement System now owns 15,104 shares of the company’s stock worth $828,000 after buying an additional 299 shares during the last quarter. Atria Investments Inc increased its position in shares of LivaNova by 6.2% during the third quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock worth $297,000 after acquiring an additional 331 shares in the last quarter. State of Alaska Department of Revenue raised its holdings in shares of LivaNova by 7.3% in the 3rd quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock worth $328,000 after acquiring an additional 425 shares during the last quarter. Rhumbline Advisers lifted its position in LivaNova by 0.4% in the 2nd quarter. Rhumbline Advisers now owns 183,132 shares of the company’s stock valued at $10,039,000 after acquiring an additional 659 shares in the last quarter. Finally, AQR Capital Management LLC boosted its stake in LivaNova by 0.7% during the 2nd quarter. AQR Capital Management LLC now owns 129,871 shares of the company’s stock valued at $7,103,000 after purchasing an additional 930 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.